{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:15:11Z","timestamp":1793394911866,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004827","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000}}],"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BC Centre for Excellence in HIV\/AIDS"},{"DOI":"10.13039\/501100004726","name":"Ministry of Health, British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100025250","name":"Vancouver Coastal Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100025250","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vancouver General Hospital Foundation"},{"DOI":"10.13039\/501100000233","name":"Genome British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000233","name":"Genome British Columbia","doi-asserted-by":"publisher","award":["GeneSolve Grant (GEN054)"],"award-info":[{"award-number":["GeneSolve Grant (GEN054)"]}],"id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV pre-exposure prophylaxis (PrEP) prevents infection when used during periods of risk, however, its population-level effectiveness is hindered by incomplete uptake, adherence, and retention. Since oral PrEP became available free-of-cost in British Columbia (BC), Canada, in January 2018, uptake has been rapid among eligible individuals, primarily comprising gay, bisexual, and other men who have sex with men (GBM), however, its effectiveness against HIV acquisition across subpopulations alongside potential effects on baseline drug resistance have not been estimated. We evaluated individual and population-level impacts of PrEP on HIV drug resistance and transmission in phylogenetic clusters, representing groups of individuals linked by recent outbreaks, to elucidate heterogeneity in its effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      Using a retrospective cohort design, we evaluated the frequencies of baseline drug resistance mutations and membership in phylogenetic clusters among newly HIV diagnosed people who ever filled a prescription for HIV PrEP (i.e., PrEP users) in BC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939) compared to non-PrEP users (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009566) diagnosed from 2018 to 2022 in the BC Drug Treatment Program with at least one sequence available. Newly HIV diagnosed PrEP users were significantly more likely than newly diagnosed non-PrEP users to be included in phylogenetic clusters (chi-squared test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0075) and carry baseline nucleoside analogue reverse transcriptase inhibitor (NRTI) resistance mutation M184I\/V (Fisher\u2019s exact test, adjusted\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.025). Subsequently, we quantified the population-level impacts of widespread PrEP availability on transmission based on the effective reproduction number (R\n                      <jats:sub>e<\/jats:sub>\n                      ), compared across key populations living with HIV in BC and active phylogenetic clusters with at least one new case since 2018. We applied simulations of active clusters\u2019 growth based on their empirically observed R\n                      <jats:sub>e<\/jats:sub>\n                      with or without estimated PrEP impacts to estimate diagnoses averted via PrEP across clusters, with non-clustered cases grouped together. Most diagnoses were averted in large and medium GBM-predominant clusters. In a Poisson model, clusters with fewer diagnoses averted were associated with having a higher median age and lower proportion of new diagnoses with PrEP use, adjusted for cluster size at the end of 2017 and proportion residing in Vancouver Coastal Health Authority. These results must be interpreted in light of uncertainty owing to incomplete sampling, the use of consensus genomes, phylogenetic inference, and the assumptions of counterfactual simulations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We estimated that the oral PrEP program in BC from 2018 to 2022 averted approximately 20 new HIV diagnoses per year across phylogenetic clusters, while infrequently contributing to baseline drug resistance in instances where PrEP was inadvertently prescribed during acute infection or with incomplete adherence. These findings corroborate the broad effectiveness of PrEP, describe heterogeneity in its impacts on clusters\u2019 growth, and suggest groups for prioritized PrEP services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004827","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T18:36:21Z","timestamp":1765305381000},"page":"e1004827","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterogeneous impacts of HIV pre-exposure prophylaxis (PrEP) on drug resistance and phylogenetic cluster transmission dynamics in British Columbia, Canada: A retrospective cohort and simulation study"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-9080","authenticated-orcid":true,"given":"Angela","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junine","family":"Toy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-8089","authenticated-orcid":true,"given":"Paul","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-0725","authenticated-orcid":true,"given":"Jason","family":"Trigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-5288","authenticated-orcid":true,"given":"Chanson J.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-9829","authenticated-orcid":true,"given":"Julio S. G.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-1482","authenticated-orcid":true,"given":"Jeffrey B.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"pmed.1004827.ref001","unstructured":"British Columbia Centre for Disease Control (BCCDC). HIV in British Columbia: Annual Surveillance Report 2017; 2017. Available from: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/STI\/HIV_Annual_Report_2017_FINAL.pdf"},{"issue":"27","key":"pmed.1004827.ref002","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1004827.ref003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"9883","key":"pmed.1004827.ref004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"K Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"pmed.1004827.ref005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/aje\/kwy230","article-title":"Addressing gaps in HIV preexposure prophylaxis care to reduce racial disparities in HIV incidence in the United States","volume":"188","author":"SM Jenness","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"3","key":"pmed.1004827.ref006","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","article-title":"FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis","volume":"66","author":"AL Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1004827.ref007","article-title":"Real-world utilization of HIV PrEP medication in a population-level PrEP program in British Columbia, Canada.","author":"J Toy","year":"2024","journal-title":"Conference on Retroviruses and Opportunistic Infections\u00a02024 Poster"},{"key":"pmed.1004827.ref008","unstructured":"Biospace. Health Canada issues notice of compliance for Gilead\u2019s Truvada for reducing the risk of sexually acquired HIV infection; 2016. Available from: https:\/\/www.biospace.com\/article\/releases\/health-canada-issues-notice-of-compliance-for-gilead-s-truvada-for-reducing-the-risk-of-sexually-acquired-hiv-infection-\/"},{"key":"pmed.1004827.ref009","unstructured":"Health Canada. Product information - APO-EMTRICITABINE-TENOFOVIR. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=93840. 2023. Accessed 2023 November 29."},{"key":"pmed.1004827.ref010","year":"2020"},{"key":"pmed.1004827.ref011","article-title":"Rapid uptake of HIV pre-exposure prophylaxis (PrEP) in a publicly funded population-based program in British Columbia, Canada","author":"KJ Toy","year":"2019","journal-title":"Conference on Retroviruses and Opportunistic Infections 2019 poster"},{"key":"pmed.1004827.ref012","doi-asserted-by":"crossref","first-page":"100461","DOI":"10.1016\/j.epidem.2021.100461","article-title":"Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?","volume":"35","author":"VD Lima","year":"2021","journal-title":"Epidemics"},{"issue":"7","key":"pmed.1004827.ref013","article-title":"Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation","volume":"11","author":"VD Lima","year":"2024","journal-title":"Lancet HIV"},{"key":"pmed.1004827.ref014","doi-asserted-by":"crossref","first-page":"100360","DOI":"10.1016\/j.epidem.2019.100360","article-title":"Predicting the impact of clustered risk and testing behaviour patterns on the population-level effectiveness of pre-exposure prophylaxis against HIV among gay, bisexual and other men who have sex with men in Greater Vancouver, Canada","volume":"30","author":"MA Irvine","year":"2020","journal-title":"Epidemics"},{"issue":"11","key":"pmed.1004827.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"AE Grulich","year":"2018","journal-title":"Lancet HIV"},{"issue":"12","key":"pmed.1004827.ref016","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26194","article-title":"Population-level effectiveness of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Montr\u00e9al (Canada): a modelling study of surveillance and survey data","volume":"26","author":"CM Doyle","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pmed.1004827.ref017","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00536-3","article-title":"Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis","volume":"12","author":"R Zhao","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"12","key":"pmed.1004827.ref018","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiw223","article-title":"Impact of the Centers for Disease Control\u2019s HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States","volume":"214","author":"SM Jenness","year":"2016","journal-title":"J Infect Dis"},{"key":"pmed.1004827.ref019","article-title":"Pre-exposure prophylaxis (PrEP) use history in people with antiretroviral resistance at HIV diagnosis: Findings from New York City HIV surveillance and partner services, 2015-2022","author":"K Misra","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pmed.1004827.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158620","article-title":"How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts\u2019 Opinion and Its Influence on the Projected Public Health Impact","volume":"11","author":"DT Dimitrov","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"pmed.1004827.ref021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11908-019-0685-6","article-title":"Update on HIV preexposure prophylaxis: effectiveness, drug resistance, and risk compensation","volume":"21","author":"VE Powell","year":"2019","journal-title":"Curr Infect Dis Rep"},{"issue":"6","key":"pmed.1004827.ref022","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug Resistance During HIV Pre-Exposure Prophylaxis","volume":"79","author":"KM Gibas","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"pmed.1004827.ref023","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"VA Fonner","year":"2016","journal-title":"AIDS"},{"issue":"6","key":"pmed.1004827.ref024","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/infdis\/jiu560","article-title":"The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada","volume":"211","author":"AFY Poon","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"pmed.1004827.ref025","article-title":"Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study","volume":"3","author":"AFY Poon","year":"2016","journal-title":"Lancet HIV"},{"key":"pmed.1004827.ref026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ebiom.2019.09.026","article-title":"Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources","volume":"48","author":"A McLaughlin","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"pmed.1004827.ref027","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/emph\/eoab028","article-title":"Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering","volume":"9","author":"A McLaughlin","year":"2021","journal-title":"Evol Med Public Health"},{"key":"pmed.1004827.ref028","first-page":"100369","article-title":"Impact of SARS-CoV-2 lockdown on expansion of HIV transmission clusters among key populations: A retrospective phylogenetic analysis","volume":"16","author":"RL Miller","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"pmed.1004827.ref029","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/emph\/eoac026","article-title":"Phylogenetic prioritization of HIV-1 transmission clusters with viral lineage-level diversification rates","volume":"10","author":"RL Miller","year":"2022","journal-title":"Evol Med Public Health"},{"issue":"1","key":"pmed.1004827.ref030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.1207965110","article-title":"Birth-death skyline plot reveals temporal changes of epidemic spread in HIV and hepatitis C virus (HCV)","volume":"110","author":"T Stadler","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"pmed.1004827.ref031","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/aje\/kwt133","article-title":"A new framework and software to estimate time-varying reproduction numbers during epidemics","volume":"178","author":"A Cori","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"7804","key":"pmed.1004827.ref032","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-020-2176-1","article-title":"Extant timetrees are consistent with a myriad of diversification histories","volume":"580","author":"S Louca","year":"2020","journal-title":"Nature"},{"issue":"9","key":"pmed.1004827.ref033","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1093\/molbev\/msab149","article-title":"Fundamental Identifiability Limits in Molecular Epidemiology","volume":"38","author":"S Louca","year":"2021","journal-title":"Mol Biol Evol"},{"issue":"18","key":"pmed.1004827.ref034","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"H Li","year":"2018","journal-title":"Bioinformatics"},{"issue":"5","key":"pmed.1004827.ref035","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/bioinformatics\/btaa743","article-title":"ViralMSA: Massively scalable reference-guided multiple sequence alignment of viral genomes","volume":"37","author":"N Moshiri","year":"2020","journal-title":"Bioinformatics"},{"issue":"18","key":"pmed.1004827.ref036","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"D Struck","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"pmed.1004827.ref037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","article-title":"Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools","volume":"19","author":"A-C Pineda-Pe\u00f1a","year":"2013","journal-title":"Infect Genet Evol"},{"issue":"11","key":"pmed.1004827.ref038","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"TF Liu","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pmed.1004827.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"DE Bennett","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"pmed.1004827.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009490","article-title":"FastTree 2--approximately maximum-likelihood trees for large alignments","volume":"5","author":"MN Price","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"pmed.1004827.ref041","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/molbev\/msx281","article-title":"UFBoot2: Improving the Ultrafast Bootstrap Approximation","volume":"35","author":"DT Hoang","year":"2018","journal-title":"Mol Biol Evol"},{"issue":"5","key":"pmed.1004827.ref042","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","article-title":"IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era","volume":"37","author":"BQ Minh","year":"2020","journal-title":"Molecular Biology and Evolution"},{"issue":"3","key":"pmed.1004827.ref043","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/bioinformatics\/bty633","article-title":"ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R","volume":"35","author":"E Paradis","year":"2019","journal-title":"Bioinformatics"},{"issue":"4","key":"pmed.1004827.ref044","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1214\/009053606000000425","article-title":"On the Benjamini\u2013Hochberg method","volume":"34","author":"JA Ferreira","year":"2006","journal-title":"Ann Stat"},{"key":"pmed.1004827.ref045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.12688\/f1000research.18002.1","article-title":"Epidemic curves made easy using the R package incidence","volume":"8","author":"ZN Kamvar","year":"2019","journal-title":"F1000Res"},{"issue":"5","key":"pmed.1004827.ref046","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/590501","article-title":"HIV-1 transmission, by stage of infection","volume":"198","author":"TD Hollingsworth","year":"2008","journal-title":"J Infect Dis"},{"issue":"11","key":"pmed.1004827.ref047","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/infdis\/jiu831","article-title":"High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men\u2014San Francisco, California","volume":"211","author":"TD Hollingsworth","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"pmed.1004827.ref048","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.amepre.2021.04.015","article-title":"Time From HIV Infection to Diagnosis in the U.S., 2014\u20132018","volume":"61","author":"AH Peruski","year":"2021","journal-title":"Am J Prev Med"},{"issue":"5","key":"pmed.1004827.ref049","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(15)70135-0","article-title":"Ebola superspreading","volume":"15","author":"CL Althaus","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pmed.1004827.ref050","doi-asserted-by":"crossref","first-page":"2000058","DOI":"10.2807\/1560-7917.ES.2020.25.4.2000058","article-title":"Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020","volume":"25","author":"J Riou","year":"2020","journal-title":"Euro Surveill"},{"issue":"7066","key":"pmed.1004827.ref051","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature04153","article-title":"Superspreading and the effect of individual variation on disease emergence","volume":"438","author":"JO Lloyd-Smith","year":"2005","journal-title":"Nature"},{"issue":"1","key":"pmed.1004827.ref052","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veaf077","article-title":"Phylogeographic evaluation of the effectiveness of Canadian travel restrictions in reducing SARS-CoV-2 variant importations and burden","volume":"11","author":"A McLaughlin","year":"2025","journal-title":"Virus Evol"},{"issue":"9790","key":"pmed.1004827.ref053","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(10)61505-X","article-title":"Mathematical models in the evaluation of health programmes","volume":"378","author":"GP Garnett","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"pmed.1004827.ref054","article-title":"Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada","volume":"20","author":"VD Lima","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pmed.1004827.ref055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1071\/SH18115","article-title":"Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program","volume":"16","author":"NJ Lachowsky","year":"2019","journal-title":"Sex Health"},{"issue":"8","key":"pmed.1004827.ref056","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","article-title":"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing","volume":"48","author":"S-Y Rhee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pmed.1004827.ref057","first-page":"136","article-title":"The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis","volume":"26","author":"M Kandeel","year":"2023","journal-title":"AIDS Rev"},{"issue":"9","key":"pmed.1004827.ref058","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jit345","article-title":"Persistence of HIV-1 transmitted drug resistance mutations","volume":"208","author":"H Castro","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"pmed.1004827.ref059","article-title":"Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds","volume":"11","author":"W-L Yang","year":"2015","journal-title":"PLoS Pathog"},{"issue":"1","key":"pmed.1004827.ref060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ve\/vex008","article-title":"Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network","volume":"3","author":"JO Wertheim","year":"2017","journal-title":"Virus Evolution"},{"issue":"2","key":"pmed.1004827.ref061","article-title":"Impacts and shortcomings of genetic clustering methods for infectious disease outbreaks","volume":"2","author":"AFY Poon","year":"2016","journal-title":"Virus Evol"},{"issue":"7","key":"pmed.1004827.ref062","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/molbev\/msy016","article-title":"HIV-TRACE (TRAnsmission Cluster Engine): a Tool for Large Scale Molecular Epidemiology of HIV-1 and Other Rapidly Evolving Pathogens","volume":"35","author":"SLK Pond","year":"2018","journal-title":"Mol Biol Evol."},{"issue":"9","key":"pmed.1004827.ref063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009347","article-title":"Improved estimation of time-varying reproduction numbers at low case incidence and between epidemic waves","volume":"17","author":"KV Parag","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"1609","key":"pmed.1004827.ref064","first-page":"599","article-title":"How generation intervals shape the relationship between growth rates and reproductive numbers","volume":"274","author":"J Wallinga","year":"2007","journal-title":"Proc Biol Sci"},{"issue":"12","key":"pmed.1004827.ref065","article-title":"HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis","volume":"10","author":"EM Volz","year":"2013","journal-title":"PLoS Med"},{"issue":"7","key":"pmed.1004827.ref066","doi-asserted-by":"crossref","DOI":"10.2196\/mhealth.9493","article-title":"Health Care Provider Utilization and Cost of an mHealth Intervention in Vulnerable People Living With HIV in Vancouver, Canada: Prospective Study","volume":"6","author":"AR Campbell","year":"2018","journal-title":"JMIR Mhealth Uhealth"},{"issue":"2","key":"pmed.1004827.ref067","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/cid\/ciad566","article-title":"Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price","volume":"78","author":"AK Amick","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pmed.1004827.ref068","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00002030-199803000-00005","article-title":"Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy","volume":"12","author":"RS Hogg","year":"1998","journal-title":"AIDS"},{"issue":"2","key":"pmed.1004827.ref069","article-title":"Expansion of HAART coverage is associated with sustained decreases in HIV\/AIDS morbidity, mortality and HIV transmission: the \u201cHIV Treatment as Prevention\u201d experience in a Canadian setting","volume":"9","author":"JSG Montaner","year":"2014","journal-title":"PLoS One"},{"issue":"9534","key":"pmed.1004827.ref070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0140-6736(06)69162-9","article-title":"The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic","volume":"368","author":"JSG Montaner","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"pmed.1004827.ref071","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11904-020-00482-6","article-title":"The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada","volume":"17","author":"VD Lima","year":"2020","journal-title":"Current HIV\/AIDS Reports"},{"key":"pmed.1004827.ref072","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7517-3-36","article-title":"HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment","volume":"3","author":"MW Tyndall","year":"2006","journal-title":"Harm Reduct J"},{"key":"pmed.1004827.ref073","unstructured":"Statistics Canada. Population estimates, quarterly. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000901. 2023. Accessed 2023 November 20."}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004827","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:52:34Z","timestamp":1765565554000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004827"}},"subtitle":[],"editor":[{"given":"Aaloke","family":"Mody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":73,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004827","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}